We found that knocking down of TAGLN2 lead to the suppression of neurosphere formation ability and cell growth of GBM#P3 cells, accompanied with the reduction of key mesenchymal markers, including CD44, CHI3L1, N-cadherin and β-catenin (Additional file 3: Fig. S3). The gene discussed is TAGLN2; the disease is glioblastoma.